Scientific programme

To reach our objectives, we propose the following activities:

- assemble and publish (on a dedicated web site) a directory of European laboratories, groups and individual researchers working on the molecular cytogenetic characterization of solid tumours for purposes of basic research or diagnostic activity. Investigators working on either the same tumours or complementary aspects of the same tumour will thus be able to establish cooperations and exchanges. Outside members will also get necessary information to communicate with the identified groups thus potentiating the European network;

- by means of the above directory and the knowledge of published and in press papers and progressed activities the management committee will set up a list of reference labs for each of the most common solid tumours. Investigators of the identified labs will be in charge of spreading information on recent key findings, relevant publications, diagnostic applications through organization of specific workshops;

- specialized groups of investigators will cooperate in setting up or updating guidelines for diagnosis of specific tumour types which will be published in the international literature together with joined studies within the network upon which they will be based;

- set up a working group for genomic resources and their application in solid tumour cytogenetics

- set up a working group responsible for technological advances on procedures and reagents aimed at improving comprehension of genetic changes in solid tumours diagnostic and prognostic applications;

General and specific topics will alternate. In the first instance, in accordance with the scheme of this COST ACTION, two main scientific areas are proposed:

- basic research area: recently disclosed cytogenetic markers of solid tumours: pathogenetic significance; development of region-specific reagents; identification of new cancer genes; updated technological devices.

- translation of new findings on molecular cytogenetics of solid tumours into laboratory services. A few cytogenetic and/or molecular markers of human tumours may be used successfully for inequivocal diagnosis, while other associated markers may have a prognostic meaning. All the chromosomal and molecular markers may serve to monitor remission and relapse of the disease.